Quantifying clinical HPV4 dose inefficiencies in a Safety Net Population

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Harper, Diane M ^a   Verdenius, Inge ^b   Ratnaraj, Felicia ^a   Arey, Anne M ^a   Rosemergey, Beth ^a   Malnar, Gerard J ^a   Wall, Jeffrey ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; CANCER PREVENTION; CANCER RISK; CHILD; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ETHNIC DIFFERENCE; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 4; IMMUNE RESPONSE; INFECTION PREVENTION; INFECTION RISK; NONHUMAN; PAPILLOMAVIRUS INFECTION; PREDICTION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; UTERINE CERVIX CANCER; VIRUS IDENTIFICATION;

ADOLESCENT; ADULT; CHILD; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HEALTH CARE COSTS; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RETROSPECTIVE STUDIES; TIME FACTORS; UTERINE CERVICAL NEOPLASMS; VACCINATION; VACCINE POTENCY; YOUNG ADULT;

EID: 84892410837     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077961     Document Type: Article

References (54)

1. CDC (2013) Vaccine Price List. Available: http://www.cdc.gov/vaccines/ programs/vfc/awardees/vaccine-management/price-list/index.html. Accessed 2013 Feb 10.
2. Goldie SJ, O'Shea M, Diaz M, Kim SY (2008) Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications. Reprod Health Matters. 16: 86-96.
3. United States Securities and Exchange Commission (2011) Merck &Co: Strategic National Stockpile of Gardasil®. 10-K SEC. Available: http://phx.corporate-ir.net/External.File?item= UGFyZW50SUQ9ODM1MDV8Q2hpbGRJRD0tMXxUeXBlPTM=&t =1. Accessed 2013 Feb 1.
4. FDA news (2008) CDC Purchased 10 Million Doses of Gardasil®. Available: http://www.fdanews.com/newsletter/article?articleId= 103084&issueId=11210. Accessed 2013 Feb 1.
5. Centers for Disease Control and Prevention (2012) National and State Vaccination Coverage Among Adolescents Aged 13 Through 17 Years - United States, 2011. MMWR. 61: 671-677.
6. Verdenius I, Harper DM, Harris GD, Griffith RS, Wall J, et al (2013) Predictors of Three Dose On-Time Compliance with HPV4 Vaccination in a Disadvantaged, Underserved, Safety Net Population in the US Midwest. PLoS ONE. 8: e71295.
7. Kessels SJ, Marshall HS, Watson M, Braunack-Mayer AJ, Reuzel R, et al (2012) Factors associated with HPV vaccine uptake in teenage girls: a systematic review. Vaccine. 30: 3546-56.
8. Gold R, Naleway AL, Jenkins LL, Riedlinger KK, Kurosky SK, et al. (2011) Completion and timing of the three-dose human papillomavirus vaccine series among adolescents attending school-based health centers in Oregon. Prev Med. 52: 456-8.
9. Niccolai LM, Mehta NR, Hadler JL (2011) Racial/Ethnic and poverty disparities in human papillomavirus vaccination completion. Am J Prev Med. 41: 428-33.
10. Rouzier R, Giordanella JP (2010) Coverage and compliance of Human Papilloma Virus vaccines in Paris: demonstration of low compliance with non-school- based approaches. J Adolesc Health. 47: 237-41.
11. Schluterman NH, Terplan M, Lydecker AD, Tracy JK (2011) Human papillomavirus (HPV) vaccine uptake and completion at an urban hospital. Vaccine. 29: 3767-72.
12. Cook RL, Zhang J, Mullins J, Kauf T, Brumback B, et al. (2010) Factors associated with initiation and completion of human papillomavirus vaccine series among young women enrolled in Medicaid. J Adolesc Health. 47: 596-9.
13. Chao C, Velicer C, Slezak JM, Jacobsen SJ (2009) Correlates for completion of 3-dose regimen of HPV vaccine in female members of a managed care organization. Mayo Clin Proc. 84: 864-70.
14. Tan W, Viera AJ, Rowe-West B, Grimshaw A, Quinn B, et al. (2011) The HPV vaccine: are dosing recommendations being followed? Vaccine. 29: 2548-54.
15. Chou B, Krill LS, Horton BB, Barat CE, Trimble CL (2011) Disparities in human papillomavirus vaccine completion among vaccine initiators. Obstet Gynecol. 118: 14-20.
16. Hirth JM, Tan A, Wilkinson GS, Berenson AB (2012) Completion of the human papillomavirus vaccine series among insured females between 2006 and 2009. Cancer. 118: 5623-5629.
17. Perkins RB, Brogly SB, Adams WG, Freund KM (2012) Correlates of human papillomavirus vaccination rates in low-income, minority adolescents: a multicenter study. J Women's Health (Larchmt). 21: 813-820.
18. Dempsey A, Cohn L, Dalton V, Ruffin M (2010) Patient and clinic factors associated with adolescent human papillomavirus vaccine utilization within a university-based health system. Vaccine. 28: 989-95.
19. Dempsey A, Cohn L, Dalton V, Ruffin M (2011) Worsening disparities in HPV vaccine utilization among 19-26 year old women. Vaccine. 29: 528-34.
20. Dorell CG, Yankey D, Santibanez TA, Markowitz LE (2011) Human papillomavirus vaccination series initiation and completion, 2008-2009. Pediatrics. 128: 830-9.
21. Neubrand TP, Breitkopf CR, Rupp R, Breitkopf D, Rosenthal SL (2009) Factors associated with completion of the human papillomavirus vaccine series. Clin Pediatr (Phila). 48: 966-9.
22. Smith LM, Brassard P, Kwong JC, Deeks SL, Ellis AK, et al. (2011) Factors associated with initiation and completion of the quadrivalent human papillomavirus vaccine series in an Ontario cohort of grade 8 girls. BMC Public Health. 11: 645.
23. Widdice LE, Bernstein DI, Leonard AC, Marsolo KA, Kahn JA (2011) Adherence to the HPV vaccine dosing intervals and factors associated with completion of 3 doses. Pediatrics. 127: 77-84.
24. Tiro JA, Pruitt SL, Bruce CM, Persaud D, Lau M, et al. (2012) Multilevel correlates for human papillomavirus vaccination of adolescent girls attending safety net clinics. Vaccine. 30: 2368-75.
25. Rubin RF, Kuttab HM, Rihani RS, Reutzel TJ (2012) Patient Adherence to Three Dose Completion of the Quadrivalent Human Papillomavirus (HPV) Vaccine in a Private Practice. J Community Health. 37: 1145-50.
26. Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, et al. (2013) Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women: A Randomized Clinical Trial. JAMA. 309: 1793-1802.
27. Smolen KK, Gelinas L, Franzen L, Dobson S, Dawar M, et al. (2012) Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine. 30: 3572-9.
28. Neuzil KM, Canh do G, Thiem VD, Janmohamed A, Huong VM, et al.(2011) Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. JAMA. 305: 1424-31.
29. Elbasha EH, Dasbach EJ (2010) Impact of vaccinating boys and men against HPV in the United States. Vaccine. 28: 6858-67.
30. Nelson JC, Bittner RC, Bounds L, Zhao S, Baggs J, et al. (2009) Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study. Am J Public Health. 99: S389-97.
31. Freeman HP, Wingrove BK (2005) Excess Cervical Cancer Mortality: A Marker for Low Access to Health Care in Poor Communities. Rockville, MD: National Cancer Institute, Center to Reduce Cancer Health Disparities, May 2005. NIH Pub. No. 05-5282. Available: http://crchd.cancer.gov/attachments/excess-cervcanmort. pdf. Accessed 2013 Jan 15.
32. Scarinci IC, Garcia FA, Kobetz E, Partridge EE, Brandt HM, et al. (2010) Cervical cancer prevention: new tools and old barriers. Cancer. 116: 2531-42.
33. FDA Approval Letter (2006) Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant. Available: http://www.fda.gov/ BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm111283.htm. Accessed 2013 Feb 1.
34. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, et al. (2007) Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 56: 1-24.
35. Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, et al. (2011) Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 103: 1444-51.
36. StatSoft Inc. (2010) STATISTICA (data analysis software system), version 9.1. Available: www.statsoft.com.
37. Harper DM, Vierthaler SL, Santee JA (2010) Review of Gardasil. Journal of Vaccines and Vaccination. 1: 107.
38. United States Securities and Exchange Commission (2012) Merck & Co., Inc. Quarterly SEC Report. Available: http://services.corporate-ir.net/SEC. Enhanced/SecCapsule.aspx?c= 73184&fid =8316959. Page 47, August, 2012.
39. United States Securities and Exchange Commission (2012) Merck & Co., Inc. Annual SEC Report. Available: http://www.merck.com/investors/financials/ annual-reports/home.html. Page 51, February, 2012.
40. Brisson M, Van de Velde N, Boily MC (2011) Different population-level vaccination effectiveness for HPV types 16, 18, 6 and 11. Sex Transm Infect. 87: 41-3.
41. Department of Health and Human Services Centers for Disease Control and Prevention (2009) Advisory Committee on Immunization Practices (ACIP) Summary Report. June 24-26, 2009. Available: http://www.cdc.gov/vaccines/acip/meetings/ minutes-archive.html. Accessed 2013 Feb 1.
42. French KM, Barnabas RV, Lehtinen M, Kontula O, Pukkala E, et al. (2007) Strategies for the introduction of human papillomavirus vaccination: modeling the optimum age- and sex-specific pattern of vaccination in Finland. Br J Cancer. 96: 514-8.
43. Rosen AB, Spaulding AB, Greenberg D, Palmer JA, Neumann PJ (2009) Patient adherence: a blind spot in cost-effectiveness analyses? Am J Manag Care. 15: 626-32.
44. Sheinfeld Gorin SN, Glenn BA, Perkins RB (2011) The human papillomavirus (HPV) vaccine and cervical cancer: uptake and next steps. Adv Ther. 28: 615-39.
45. Grant D, Hurley J, Williams H (2012) Department of Health and Human Services. Office of Inspector General. Vaccines for Children Program: Vulnerabilities in vaccine management. OEI-04-10-00430 June 2012. Available: https://oig.hhs.gov/oei/reports/oei-04-10-00430.asp. Accessed 2013 Feb 1.
46. Harper DM Vierthaler SL (2011) Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females. ISRN Obstet Gynecol. 2011: 457204.
47. Kuehn BM. (2011) Two doses of HPV vaccine may be sufficient. JAMA. 306: 1643.
48. Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, et al. (2011) Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule: Results from a randomized study. Hum Vaccin. 7: 1374-86.
49. Zimmerman RK, Nowalk MP, Lin CJ, Fox DE, Ko FS, et al. (2010) Randomized trial of an alternate human papillomavirus vaccine administration schedule in college-aged women. J Womens Healt. 19: 1441-7.
50. Setia S, Mainzer H, Washington ML, Coil G, Snyder R, et al. (2002) Frequency and causes of vaccine wastage. Vaccine. 20: 1148-56.
51. Moyer VA (2012) U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 156: 880-91.
52. Goldie SJ, Diaz M, Kim SY, Levin CE, van Minh H, et al. (2008) Mathematical Models of Cervical Cancer Prevention in the Asia Pacific Region. ICO HPV Monograph Series: Asia Pacific Regional Report. Vaccine 26S: M17-M29.
53. Centers for Disease Control and Prevention (CDC) (2012) Human papilloma-virus-associated cancers - United States, 2004-2008. MMWR Morb Mortal Wkly Rep. 61: 258-61.
54. Harper DM, Williams KB (2010) Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies. Discov Med. 10: 7-17.